Was it a home run, No. Was it positive,Yes.
The secondary endpoints and full analysis will reveal more.
Failure is when the primary endpoint fails. Didn't happen.
To me, any reduction in the % who get severe OM is a victory that increases SOC.
The prevention of onset and/or potential for time reduction in any stage of OM adds to its value.
More specific dosages over all is needed.
It is huge IMO that it is an oral rinse. Enough poison given already through chemo.
Until I see the total data, yes, I think the negative nancies have over-reacted.
I bet not one of them has experienced severe chemo side effects, been in an infusion room seemingly endlessly or sat at the bedside of a hospitalized OM sufferer. The misery is unimaginable. There are no words.
I have no idea what the end is, but I still think it has great promise to at least have significant market share if not SOC. More data is needed.
IMO for investors there is no better voice of reason than BioHedge. There are also some obviously competent posters on the science. Everyone else is just noise. All IMO.
Course, lol, there a few wonderfully talented technical posters as well. ;-)
News 
Market Data 
Discover 
